Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer

• 1. 通过综合组学分析研究患有转移性三阴性乳腺癌的患者的肿瘤和时间异质性 [P] . 中国专利： CN110719961A . 2020-01-21
• 2. 转移性疾病中循环肿瘤细胞的单细胞基因组图谱分析以表征疾病异质性 [P] . 中国专利： CN108884494A . 2018-11-23
• 3. INVESTIGATING TUMORAL AND TEMPORAL HETEROGENEITY THROUGH COMPREHENSIVE -OMICS PROFILING IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER [P] . EP3631003A4 . 2021-03-10

  机译： 通过转移三重阴性乳腺癌患者的综合 - 综合性分析来研究肿瘤和时间异质性

• 4. INVESTIGATING TUMORAL AND TEMPORAL HETEROGENEITY THROUGH COMPREHENSIVE -OMICS PROFILING IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER [P] . 欧洲知识产权局专利： EP3631003A1 . 2020-04-08

  机译： 通过综合肌组学研究转移性三阴性乳腺癌患者的颞叶和颞叶异质性

• 5. Investigating tumoral and temporal heterogeneity through comprehensive -omics profiling in patients with metastatic triple negative breast cancer [P] . IL271076D0 . 2020-01-30

  机译： 通过综合组学分析研究转移性三阴性乳腺癌患者的肿瘤和时间异质性

• 1. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer [J] . Xiaoran Liu, Guohong Song, Hanfang Jiang, 中国癌症研究（英文版） . 2018,第003期
• 2. ID7 Isolated from Bauhinia variegata Stem Inhibits Tumor Progression and Metastatic Mechanisms of Triple Negative Breast Cancer in Vivo [J] . Kamilla Monteiro dos Santos, Izabela Natalia Faria Gomes, Renato JoséSilva Oliveira, 药剂与药理学：英文版 . 2019,第007期
• 3. Searching for Better Outcomes among Patients with Metastatic Triple- Negative Breast Cancer – Do We Have Novel Options on the Treatment Landscape? [J] . Katarzyna(Kate)Rygiel 现代肿瘤学研究进展(英文) . 2020,第001期
• 4. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer [J] . Xu Liang, Lijun Di, Guohong Song, 中国癌症研究（英文版） . 2014,第005期
• 5. Multi-omics profiling reveals metabolic heterogeneity of triple-negative breast cancer [J] . Gong Y., Ji P., Yu T. -J., The Breast : . 2019,第期
• 6. Multi-omics profiling reveals metabolic heterogeneity of triple-negative breast cancer [J] . Gong Y., Ji P., Yu T. -J., The Breast : . 2019,第Suppla1期
• 7. Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. [J] . Koshy N, Quispe D, Shi R, The Breast : . 2010,第3期
• 8. Single Cell Genomic Profiling of Circulating Tumor Cells (CTCs) from Metastatic Colorectal Cancer (mCRC) Identify Tumor Heterogeneity and Rare Somatic Driver Alterations [C] . Stephanie Greene, Angel Rodriguez, Jerry Lee, International Molecular Medicine Tri-Conference. . 2016
• 9. Investigation of Intra-tumour Heterogeneity and Host Immune Response in Triple-Negative Breast Cancer [D] . Balde, Zaldy Sirios. 2020
• 10. Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer [O] . Jonas Steenbrugge, Niels Vander Elst, Kristel Demeyere, 2019
• 11. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer [O] . 2016

• 1. Treatment Patterns and Mortality Risk among Elderly Patients with Metastatic Triple Negative Breast Cancer in the United States: An Observational Cohort Study Using SEER-Medicare Data [J] . Sacha Satram-Hoang ,Preeti Bajaj ,Alisha Stein . 癌症治疗（英文） . 2019,第2期
• 2. 肿瘤标志物CEA、CA153、CA125和循环肿瘤细胞(CTC)的检测对转移性乳腺癌患者预后的预测价值 [C] . 钱六七 ,江泽飞 ,刘芊 . 第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 . 2012
• 3. 循环肿瘤DNA分析监测转移性乳腺癌患者抗肿瘤治疗疗效的探索性研究 [A] . 易宗毕 . 2018